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ORIGINAL ARTICLE
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ABSTRAK
Tujuan: untuk menilai keamanan dan efektifitas dari penggunaan kombinasi tetap artemeter-lumefantrine
terhadap kegagalan terapi artesunat-amodiaquine lini pertama. Metode: studi ini merupakan penelitian terbuka
tunggal tanpa kontrol. Kami menilai penggunaan terapi standar artemeter-lumefantrine terhadap 59 subyek
dengan malaria tanpa komplikasi yang disebabkan oleh Plasmodium falciparum di pulau Sumba, Indonesia Timur.
Tidak ada kegagalan terapi hingga hari ke-35. Seorang subjek memiliki parasitemia rekuren pada hari ke-42
yang menunjukkan genotipe konsisten dengan rekrudesensi yang terjadi. Sehingga, efikasi terapi ini diperkirakan
sebesar 98,3% (95% CI = 95%-100%). Analisis deskriptif dilakukan dengan menggunakan SPSS versi 12.
Hasil: dua ratus tiga belas subyek dengan P. falciparum yang memenuhi kriteria inklusi dalam studi kemanjuran
in vivo, 79 subyek diberi artemeter-lumefantrine dan 134 subyek diterapi dengan protokol lain menggunakan
artesunat-amodiaquine atau sulfadoksin-pirimetamin. Di antara 79 subyek yang memenuhi kriteria, 59 subyek
berhasil menyelesaikan pemeriksaan yang berlangsung selama 42 hari. Seperti yang diharapkan, nilai rerata
PCT lebih lama dibandingkan nilai rerata FCT, yaitu masing-masing sebesar 1,34+0,67 (95% CI 1,21-1,47)
dan 1,05+0,05 (95% CI 0,95-1,15) hari. Pada hari ke-3 pengobatan, baik demam maupun fase aseksual
P. falciparum menghilang pada semua subyek. Pengamatan sampai hari ke-35 menunjukkan bahwa 59 subyek
yang diobati dengan artemeter-lumefantrine ternyata sembuh. Kesimpulan: temuan dari studi tanpa kontrol ini
menunjukkan keamanan dan efikasi yang baik artemeter-lumefantrine untuk pengobatan malaria falciparum
tanpa komplikasi di Pulau Sumba dan Kepulauan Sunda Kecil di Indonesia.
Kata kunci: Artemisinin, artemeter-lumefantrin, Plasmodium falciparum, Indonesia.
ABSTRACT
Aim: to evaluate the safety and efficacy of a fixed combination of artemether-lumefantrine for likely use
against failures of the artesunate-amodiaquine first line therapy. Methods: the study was an open label single
arm uncontrolled trial. we evaluated the safety and efficacy of standard artemether-lumefantrine therapy in
59 subjects with uncomplicated malaria caused by Plasmodium falciparum on the island of Sumba in eastern
Indonesia. No treatment failures occurred up to day 35. One subject had recurrent parasitemia on day 42 that
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showed a genotype consistent with recrudescence. The efficacy of this therapy was thus estimated to be 98.3%
(95% confidence interval=95%-100%). Descriptive analysis was done using the SPSS 12 computer software.
Results: two hundred and thirteen P. falciparum patients met the inclusion criteria for in vivo efficacy study, 79
were given artemether-lumefantrine and 134 were treated under another protocol with artesunate-amodiaquine or
sulfadoxine-pyrimethamine. Among 79 eligible subjects, 59 successfully completed the 42-day test. As expected, the
mean PCT was longer than the mean FCT, i.e. 1.34+0.67 (95% CI 1.21–1.47) and 1.05+0.05 (95% CI 0.95–1.15)
days, respectively. On day 3 of treatment, both fever and asexual stage of P. falciparum disappeared in all subjects.
Observation until Day 35 showed that all of the 59 subjects treated with artemether-lumefantrine were cured.
Conclusion: the findings of this uncontrolled study suggest good safety and efficacy of artemether-lumefantrine
for treatment of uncomplicated falciparum malaria on Sumba Island in the Lesser Sundas archipelago of eastern
Indonesia.
Key words: Artemisinin, artemether-lumefantrine, Plasmodium falciparum, Indonesia.
INTRODUCTION

In Indonesia chloroquine treatment failure
during P. falciparum malaria ranges from
25%--99% in almost every major island of this
archipelago nation.1-3 Biomolecular studies of P.
falciparum gene mutations linked to chloroquine
resistance (pfcrt single nucleotide polmorphisms)
tend to corroborate the in vivo findings from the
field.4-5
The Indonesian Ministry of Health finally
replaced chloroquine as the first-line therapy for
uncomplicated falciparum malaria in 2004, selecting
the combination of artesunate-amodiaquine.6 The
principal appeal to artesunate-amodiaquine as the
drug of choice for the treatment of P. falciparum
infection was the fact that amodiaquine was
never before used in this country and its lower
cost as compared to artemether-lumefantrine.
Nevertheless, the high resistance rate of P.
falciparum to chloroquine in almost all provinces
in Indonesia, coupled with the possibility of cross
resistance between chloroquine and amodiaquine
have cast doubts on the sustainable efficacy of
artesunate-amodiaquine.7-8 Due to low compliance
of seven days quinine and doxycycline as the current
second line, Indonesia might consider the adoption
of artemether-lumefantrine as alternative.Therefore,
this study explored the safety and efficacy of a fixed
combination of artemether-lumefantrine for likely
use against failures of the artesunate-amodiaquine
first line therapy.
This study was conducted at the Waingapu
Primary Health Center, Eastern Sumba district,
Sumba Island in Eastern Nusatenggara province,
from February to September 2004. Like other
regions of Indonesia, Sumba has dry (May
to November) and rainy (December to April)
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seasons. At the time of this study chloroquine and
sulfadoxine-pyrimethamine were still the firstand the second-line therapies against falciparum
malaria. However, in 2002, in vivo studies on
these drugs in Eastern Nusatenggara, revealed
that the failure rates of chloroquine were 65%
and 69% on Western Sumba and Alor island,
respectively, and 8.5% in Alor for sulfadoxinepyrimethamine.9-10
METHODS

The study was an open labeled single arm
uncontrolled trial. The inclusion criteria were
in accordance with those recommended by the
WHO.11 All subjects gave written informed
consent. This research protocol was approved
by the Committee of Medical Research Ethics of
the Faculty of Medicine, University of Indonesia,
Jakarta.
The eligible patients were then given
Coartem® (Novartis) orally, which contains 20
mg artemether and 120 mg lumefantrine in fixed
combination, with the following dosage: body
weight from 10 to14 kg: 2 x 1 tablet daily, BW
from 15 to 24 kg: 2 x 2 tablets daily, BW from
25 to 34 kg: 2 x 3 tablets daily, BW from 35 kg
and above: 2 x 4 tablets daily. The drug was given
for a total of 3 days. The morning dose and the
evening dose were given in the Waingapu Health
Centre under direct supervision.
All subjects were followed up for 42 days
and asked to return to the health centre on days
1, 2, 3, 7, 14, 21, 28, 35, and 42. At each visit
the axillary temperature was taken using a
digital thermometer. Thick and thin blood films
and blotting on Whatman filter paper no.1 for
parasite genotyping were made by blood samples
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obtained by finger prick.
The observation of each patient ended if
the treatment failed (becoming parasitemic),
succeeded (remaining free of parasitemia up to
day 42), or if lost to follow up, withdrawal from
the study, or protocol violation.
All adverse event data were collected from
the patients in a yes-or-no form during their
follow-up visits. If the adverse events started
at day 0 and vanished concomitantly with the
disappearance of fever and/or parasitemia, a
disease-related causality was assumed. If the
adverse event persisted despite disappearance
of parasite and fever, a drug-related causality
was explored.
Parasite clearance time was determined
from the first day of drug administration until
its disappearance and persisted for 2 days. Fever
clearance time was only evaluated in patients
having fever on day 0 and measured at the point
at which body temperature fell to <37.50C and the
patient remained apyretic for 2 subsequent days.
Blood samples for genetic analysis from
patients were taken prior to treatment and at the
time of treatment failure. This technique was
applied to discriminate whether reapperance of
parasitemia during follow up period originally
from new infection or a recrudescence of old
infection. Microscopic examination was not
able to differentiate these two condiritons,
but merozoite surface protein-2 genotyping
discriminated recrudescence from re-infection.
Real-time quantitative PCR, using LightCycler
system (Roche Applied Science), was performed
with fluorescent SYBR Green 1 dye binding
specifically to double-stranded DNA.12 PCR
product identity was assessed by the specific
melting temperature obtained for each genotype
and confirmed by gel electrophoresis migration.
Descriptive analysis was done using the
SPSS 12 computer software. Only patients having
taken 6 doses of drug and classified as “failed”
or “successful” were included in the per-protocol
analysis.
RESULTS

Blood examination was done on 2,278
patients who came to the Waingapu Primary
Health Center suspected of having malaria. A
total of 23% (525) had slide-proven malaria
with P. falciparum (356) the dominant species
followed by P. vivax (119), mixed infection of the

two species (47), and P. malariae (3), respectively.
Two hundred and thirteen P. falciparum
patients met the inclusion criteria for in vivo
efficacy study, 79 were given artemetherlumefantrine and 134 were treated under
another protocol with artesunate-amodiaquine
or sulfadoxine-pyrimethamine (Sutanto et al,
unpublished). Twenty out of 79 patients were then
not included in per-protocol analysis for several
reasons. Three were hospitalized on the first day
of artemether-lumefantrine treatment. The reason
of hospitalization of the 3 patients were vomiting,
diarrhea and high fever (>390C). These symptoms
were due to malaria disease, but were not related
to the treatment. They were then given intravenous
quinine and all were discharged from the hospital
after 3 days. The other 12 were found to have
P. vivax infection during the 42-day follow-up
period. Four patients were lost to follow-up on
day 28 (1 subject) or day 42 (3 subjects). One
subject was exluded with evidence of P. falciparum
reinfection as indicated by the PCR test showed
3D7-type at admission and FC27-type on day 42,
was therefore classified as having been reinfected.
In summary, among 79 eligible subjects, 59
successfully completed the 42-day test.
As expected, the mean PCT was longer than
the mean FCT, i.e. 1.34 + 0.67 (95% CI 1.21 –
1.47) and 1.05 + 0.05 (95% CI 0.95 – 1.15) days,
respectively. On Day 3 of treatment, both fever
and asexual stage of P. falciparum disappeared
in all subjects.
Observation until Day 35 showed that all of the
59 subjects treated with artemether-lumefantrine
were cured. On day 42, however, parasitemia
had reappeared in 1 subject. Genotyping analysis
showed that one had identical 3D7-type alleles
at admission and failure (d42), confirming
recrudescence. Therefore, the corrected of cure
rate on day 42 was 98.3% (58/59). The summary
of recruitment patients until the outcomes of in
vivo study is showed in Figure 1.
Gametocytemia occurred in 18 (30.5%)
subjects in this study. In 8 (13.6%) cases
gametocytemia was identified prior to treatment,
while in 10 (16.9%) it was found during the
treatment period (six, three and one persons
on days 1, 2 and 3, respectively). Thereafter, a
consistent disappearance of gametocyte till day
42 was observed in all cases. The mean length of
the gametocytemia was 2.5 days (95% CI 1.59 –
3.41, range 1 – 6 days).
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The most frequent of physical complaints on
day of recruitment were headache and nausea,
which were 86.2% and 67.8%, respectively.
Other complaints were far less common (Figure
2). Complaint of headache became 16.9% on day7 and persisted to day 42 in 5% of these subjects.
DISCUSSION

In the present study artemether-lumefantrine
proved safe and highly efficacious in 59 residents
of eastern Sumba Island presenting with
uncomplicated falciparum malaria. Another study
in southern Papua of Indonesia, an area with
multidrug resistant P. falciparum also showed
high cure rate (95.3%) of artemether-lumefantrine
after PCR correction.13 The intensity of malaria
transmission over the Indonesian archipelago
varies widely among endemic areas, and pattern
of drug resistance shift over both geographic
area and time. Therefore, decision for treatment
policy is more complex here than in other
malaria countries. However, these two studies

(Sumba and Papua) demonstrated good efficacy
of the artemether-lumefantrine consistently.
Other studies outside Indonesia also had shown
that artemether-lumefantrine effective for P.
falciparum in areas of low to high level of malaria
transmission, in non immune or semi immune
infected children, in addition to the multidrug
resistant parasite, with efficacy of 93.6%, 93%,
95%, 93.3% and 95.5%, respectively.14-17
Serious adverse events of the three hospitalized
patients in this study could not only be attributed
to the drug reactions itself, considering that
headache and gastrointestinal disturbances were
documented as major symptoms of patients on
admission. All these patients were discharged
from hospital without any sequelae. Therefore
tolerance to artemether-lumefantrine in this study
was deliberately good.
Although this study showed good efficacy
and tolerance of artemether-lumefantrine for
P. falciparum cases, the high cost of the drug
and its ineffectiveness to P. vivax as the other
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dominant species in Indonesia, limits artemetherlumefantrine utilization as second line therapy
to P. falciparum. The current second line for
P. falciparum cases in Indonesia is seven
days combination of quinine and doxycycline
or tetracycline. The low compliance of this
combination due to chinchonism makes it as
unfavorable choice both for doctors and patients.
Therefore, this study is important as preliminary
data for searching a better second line therapy.
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